Perrigo Company Overview

  • Year Founded
  • 1887

Year Founded

  • Status
  • Public

  • Employees
  • 8,379

Employees

  • Stock Symbol
  • PRGO

Stock Symbol

  • Investments
  • 52

  • Share Price
  • $27.53
  • (As of Friday Closing)

Perrigo Company General Information

Description

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Contact Information

Website
www.perrigo.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • The Sharp Building
  • Hogan Place
  • Dublin
  • Ireland
+353 (01)
Primary Industry
Pharmaceuticals
Stock Exchange
NYS
Vertical(s)
Corporate Office
  • The Sharp Building
  • Hogan Place
  • Dublin
  • Ireland
+353 (01)

Perrigo Company Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Perrigo Company Stock Performance

As of 11-Jul-2025, Perrigo Company’s stock price is $27.53. Its current market cap is $3.75B with 137M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$27.53 $27.27 $23.14 - $30.93 $3.75B 137M 1.19M -$1.31

Perrigo Company Financials Summary

As of 31-Mar-2025, Perrigo Company has a trailing 12-month revenue of $4.34B.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 6,885,600 6,798,459 8,021,899 8,232,169
Revenue 4,335,200 4,373,400 4,655,600 4,451,600
EBITDA 534,300 433,000 525,000 355,500
Net Income (180,300) (171,800) (12,700) (140,600)
Total Assets 9,759,800 9,647,700 10,809,100 11,017,300
Total Debt 3,627,500 3,618,100 4,073,400 4,106,600
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Perrigo Company Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Perrigo Company‘s full profile, request access.

Request a free trial

Perrigo Company Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and
Pharmaceuticals
Dublin, Ireland
8,379 As of 2024

Hyderabad, India
 

Montreal, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Perrigo Company Competitors (37)

One of Perrigo Company’s 37 competitors is Dr. Reddy's Laboratories, a Corporation company based in Hyderabad, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dr. Reddy's Laboratories Corporation Hyderabad, India
Knight Therapeutics Corporation Montreal, Canada
Eisai Corporation Tokyo, Japan
Viatris Corporation Canonsburg, PA
Sandoz Group Corporation Basel, Switzerland
You’re viewing 5 of 37 competitors. Get the full list »

Perrigo Company Patents

Perrigo Company Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240415163-A1 Flavor banding of capsules Pending 16-Jun-2023
US-11793876-B2 Bulk polyethylene glycol compositions Active 18-Oct-2019
US-20210113698-A1 Bulk polyethylene glycol compositions Active 18-Oct-2019
US-11701350-B2 Dextromethorphan extended release pharmaceutical composition Active 22-Jul-2019
US-20210023073-A1 Dextromethorphan extended release pharmaceutical composition Active 22-Jul-2019 A61K31/485
To view Perrigo Company’s complete patent history, request access »

Perrigo Company Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Perrigo Company Investments & Acquisitions (52)

Perrigo Company’s most recent deal was a Corporate Asset Purchase with Nestle (Gateway Infant Formula Plant based in Eau Claire, Wisconsin) for . The deal was made on 01-Nov-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Nestle (Gateway Infant Formula Plant based in Eau Claire, Wisconsin) 01-Nov-2022 Corporate Asset Purchase Buildings and Property
HRA Pharma 29-Apr-2022 Merger/Acquisition Pharmaceuticals
Sanofi (Emolium, Iwostin and Loxon in Paris, France) 02-Nov-2020 Corporate Asset Purchase Buildings and Property
Kazmira 17-Jun-2020 Corporate Real Estate Investment Trusts (REITs)
Dr. Fresh 02-Apr-2020 Merger/Acquisition Personal Products
You’re viewing 5 of 52 investments and acquisitions. Get the full list »

Perrigo Company ESG

Risk Overview

Risk Rating

Updated July, 01, 2025

33.85 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,697

Rank

Percentile

Household Products

Industry

of 104

Rank

Percentile

Personal Products

Subindustry

of 81

Rank

Percentile

To view Perrigo Company’s complete esg history, request access »

Perrigo Company Exits (5)

Perrigo Company’s most recent exit was on 28-Aug-2015 from Mitchell-Vance Laboratories. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Mitchell-Vance Laboratories 28-Aug-2015 Completed
Rosemont Pharmaceuticals 11-Feb-2013 Completed
IVC Brunel Healthcare 01-Jan-2003 Completed
Sagmel 01-Jan-1997 Completed
Vi-Jon 01-Dec-1994 Merger/Acquisition Completed
To view Perrigo Company’s complete exits history, request access »

Perrigo Company Affiliates

Subsidiaries (13)

Name Industry Location Year Founded
Perrigo Ireland 10 Unlimited Company Dublin, Ireland 2015
Perrigo Ireland 5 Unlimited Company Dublin, Ireland 2015
Omega Pharma Austria Health Care Vienna, Austria 2013
Perrigo Finance Unlimited Company Dublin, Ireland 2004
Perrigo Uk Acquisition Braunton, United Kingdom 2001
You’re viewing 5 of 13 affiliates. Get the full list.  »

Perrigo Company FAQs

  • When was Perrigo Company founded?

    Perrigo Company was founded in 1887.

  • Where is Perrigo Company headquartered?

    Perrigo Company is headquartered in Dublin, Ireland.

  • What is the size of Perrigo Company?

    Perrigo Company has 8,379 total employees.

  • What industry is Perrigo Company in?

    Perrigo Company’s primary industry is Pharmaceuticals.

  • Is Perrigo Company a private or public company?

    Perrigo Company is a Public company.

  • What is Perrigo Company’s stock symbol?

    The ticker symbol for Perrigo Company is PRGO.

  • What is the current stock price of Perrigo Company?

    As of 11-Jul-2025 the stock price of Perrigo Company is $27.53.

  • What is the current market cap of Perrigo Company?

    The current market capitalization of Perrigo Company is $3.75B.

  • What is Perrigo Company’s current revenue?

    The trailing twelve month revenue for Perrigo Company is $4.34B.

  • Who are Perrigo Company’s competitors?

    Dr. Reddy's Laboratories, Knight Therapeutics, Eisai, Viatris, and Sandoz Group are some of the 37 competitors of Perrigo Company.

  • What is Perrigo Company’s annual earnings per share (EPS)?

    Perrigo Company’s EPS for 12 months was -$1.31.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »